The Hague Court of Appeal revoked Bayer’s Dutch rivaroxaban dosage patent (EP 961) for lack of inventive step. The judgment overturns the 2023 first instance decision, dismisses Bayer’s infringement claims against Sandoz and aligns the Netherlands with several foreign courts.

Recent UPC rulings confirm and expand its cross-border jurisdiction in patent disputes. The Court of Appeal clarifies how jurisdiction can be established, strengthening the UPC’s role as a one-stop forum for European patent litigation.

The Hague Court upholds enzalutamide patent, rejecting generics’ invalidity claims due to hindsight-based reasoning.

Sandoz’ and Teva’s invalidity arguments were dismissed and an injunction against Sandoz was awarded.

By judgment of 15 August 2023 in PI proceedings brought by Bristol-Myers Squibb, the Court of Appeal of The Hague prohibited Sandoz, Stada and Teva from marketing generic apixaban.

The Unified Patent Court has the potential to change a lot about how inventions are protected in European patent practice. The UPC brings both certainty and uncertainty and has advantages, but certainly also disadvantages.

In ‘State of the Art’, our lawyers from the IP & Technology practice group share their expertise on the main themes and current developments within information law.

By decision of 11 January 2023, the District Court of The Hague (the Court) rejected Nokia’s claim for a preliminary injunction against Oleading B.V. and Reflection Investment B.V. (Oppo Distributors) regarding the alleged infringement of Standard Essential Patents (SEPs).

On 7 September 2022, the District Court of The Hague (“the Court”) rendered judgment in two final relief proceedings between Orope Germany GmbH (“Orope Germany”) and Nokia Solutions and Networks OY (“Nokia”) regarding the alleged invalidity of two of Nokia’s SEPs.

The Court of Appeal of The Hague affirms the first instance decision in which the PI judge of the District Court rejected Novartis’ claim for a preliminary injunction against Mylan.

In its interim relief decision of 21 June 2022 the PI Judge of the District Court of The Hague held Novartis’ EP 2 959 894 (“EP 894”) re fingolimod 0.5 mg provisionally invalid. This is the first substantive PI decision on this matter in Europa, where several proceedings between Novartis and Mylan are pending.